Vancomycin Hydrochloride Patent Expiration
Vancomycin Hydrochloride is Used for treating bacterial infections in the gastrointestinal tract. It was first introduced by Ani Pharmaceuticals Inc
Vancomycin Hydrochloride Patents
Given below is the list of patents protecting Vancomycin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vancomycin Hydrochloride | US10039804 | Glycopeptide compositions | Nov 06, 2035 | Hikma |
| Vancomycin Hydrochloride | US10188697 | Glycopeptide compositions | Nov 06, 2035 | Hikma |
| Vancomycin Hydrochloride | US10849956 | Glycopeptide compositions | Nov 06, 2035 | Hikma |
| Vancomycin Hydrochloride | US11517609 | Glycopeptide compositions | Nov 06, 2035 | Hikma |
| Vancomycin Hydrochloride | US11628200 | Glycopeptide compositions | Nov 06, 2035 | Hikma |
| Vancomycin Hydrochloride | US12161690 | Glycopeptide compositions | Nov 06, 2035 | Hikma |
| Firvanq Kit | US10493028 | Composition and method for vancomycin oral liquid | Mar 13, 2035 | Azurity |
| Firvanq Kit | US10688046 | Composition and method for vancomycin oral liquid | Mar 13, 2035 | Azurity |
| Firvanq Kit | US10959946 | Composition and method for vancomycin oral liquid | Mar 13, 2035 | Azurity |
| Firvanq Kit | US10959947 | Composition and method for vancomycin oral liquid | Mar 13, 2035 | Azurity |
| Firvanq Kit | US10959948 | Composition and method for vancomycin oral liquid | Mar 13, 2035 | Azurity |
| Firvanq Kit | US10959949 | Composition and method for vancomycin oral liquid | Mar 13, 2035 | Azurity |
| Firvanq Kit | US11638692 | Composition and method for vancomycin oral liquid | Mar 13, 2035 | Azurity |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Vancomycin Hydrochloride's patents.
Latest Legal Activities on Vancomycin Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Vancomycin Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 May, 2024 | US10849956 |
| Electronic Review Critical
| 19 May, 2023 | US11628200 |
| Email Notification Critical
| 19 May, 2023 | US11628200 |
| Miscellaneous Communication to Applicant - No Action Count | 18 May, 2023 | US11628200 |
| Mail Miscellaneous Communication to Applicant | 18 May, 2023 | US11628200 |
| Electronic Review Critical
| 21 Apr, 2023 | US11628200 |
| Email Notification Critical
| 21 Apr, 2023 | US11628200 |
| Mail Miscellaneous Communication to Applicant | 21 Apr, 2023 | US11628200 |
| Miscellaneous Communication to Applicant - No Action Count | 18 Apr, 2023 | US11628200 |
| Patent Issue Date Used in PTA Calculation Critical
| 18 Apr, 2023 | US11628200 |
Vancomycin Hydrochloride's Family Patents
